FIELD: medicine, neurology. SUBSTANCE: invention relates to use of selegiline [L-N-(1-phenylisopropyl)-N- -methyl-N-propinylamine] or its pharmaceutically acceptable salts for treatment of patients with epileptic diseases. EFFECT: decreased duration of epileptic seizures, delayed progression of disease. 3 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION EXHIBITING ANTICONVULSANT AND ANALGETIC ACTIVITY | 1990 |
|
RU2120796C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH EPILEPSY | 1997 |
|
RU2144355C1 |
| 3-AMINOPYRROLS AND PHARMACEUTICAL AGENT SHOWING ANTICONVULSIVE ACTION | 1990 |
|
RU2060991C1 |
| METHOD FOR DIAGNOSING AND PREDICTING EPILEPSY DEVELOPMENT IN PATIENTS AT PRECLINICAL DISEASE STAGE | 2001 |
|
RU2189776C1 |
| METHOD OF TREATING EPILEPSY | 2012 |
|
RU2522990C2 |
| METHOD OF REHABILITATION OF PATIENTS WITH ALCOHOLISM | 2009 |
|
RU2436573C2 |
| USE OF PROBENECID FOR TREATMENT OF EPILEPTIC DISEASES, DISORDERS AND CONDITIONS | 2018 |
|
RU2785842C2 |
| APPLICATION OF 1-AR(ALK)YLIMIDAZOLINE-2- ONS IN TREATING STATE OF FEAR AND ANXIETY | 1998 |
|
RU2203055C2 |
| PYRAZOLE[3,4-D]PYRIMIDINES SHOWING ANTICONVULSANT AND ANTIALLERGIC/ANTIASTHMATIC EFFECT, METHODS OF THEIR SYNTHESIS (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2194050C2 |
| ANTICONVULSANT | 2014 |
|
RU2572711C1 |
